TGFβ signaling in glioblastoma

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 175 CE courses, most popular
$109Add to cart
Pick Your Courses
Up to 8 CE hours
$55Add to cart
Individual course$25Add to cart
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Hallmarks and Signaling of Cancer Cells. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Hallmarks and Signaling of Cancer Cells (online CE course)
TGFβ signaling in glioblastoma

Glioblastoma multiforme (GBM) is the most aggressive grade of glioma with no known cure.
Scientists at Memorial Sloan Kettering Cancer Center (MSKCC) have observed a correlation between GBM's poor prognosis and high levels of TGFβ. Hence, the TGFβ signaling pathway (Figure 5) is an attractive target for drug development. LY2157299 (made by Eli Lily) is one such TGFβ inhibitor that is currently undergoing clinical trials. Specifically, LY2157299 blocks the TGFβ receptor I (RI), hence blocking the entire TGFβ signaling cascade.
Among many factors that contribute to challenges in cancer treatment is complex, context-dependent signaling. Take TGFβ as an example, it is anti-proliferative and immune suppressive under healthy conditions. However, in cancerous conditions, especially late-stage cancer, TGFβ has been found to promote cell proliferation, angiogenesis, and metastasis.